SARS-CoV-2-specific immune responses after two versus three doses COVID-19 vaccination in end-stage renal disease patients and kidney transplant recipients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210524002

Enrollment

120

Registered

2021-05-24

Start date

2021-08-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 renal transplant, immunogenicity, safety, humoral immunity, cell-mediated immunity

Interventions

Three doses of SARS-CoV-2 vaccine to those with blunted immune responses to two doses of SARS-CoV-2 vaccine

Experimental Biological/Vaccine

Three doses of SARS-CoV-2 vaccine

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All adult ESRD, either HD or PD, and kidney transplant recipients

Exclusion criteria

Exclusion criteria: Active infection Allograft rejection Previous COVID-19 infection Receiving COVID-19 vaccine prior to including in the study

Design outcomes

Primary

Measure	Time frame
Immunogenicity 4 weeks after the last vaccine dose SARS-CoV-2 specific immune responses	—

Secondary

Measure	Time frame
Safety 4 weeks after the last vaccine dose Adverse reactions	—

Countries

Thailand

Contacts

Public ContactJackrapong Bruminhent

Faculty of Medicine Ramathibodi Hospital, Mahidol University

jbruminhent@gmail.com022011581

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026